PML risk stratification using anti-JCV antibody index and L-selectin.
about
Current status of biomarker research in neurologyNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drugDiagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathyThe future of multiple sclerosis treatments.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.JCV serology in time: 3 years of follow-up.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologica[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].The effect of disease modifying therapies on CD62L expression in multiple sclerosis
P2860
Q26744505-7750192F-1586-44BF-AB01-8BD859DCCE6CQ30699740-0351AE34-40C2-45F4-9BDB-36C7AAB153D8Q33693085-E3BD2B03-89DD-4468-BC63-A0AA31A680B1Q36073992-01B9F051-E522-439B-9292-0D74B91A85F5Q36521237-726B5F0D-1ED3-4B56-9816-D9D25C99CA2AQ36942417-AB9D3BBD-0B4D-40E5-B115-C9191A4E78F8Q38808485-AFC6161F-CE39-4A35-9CB0-904EEE960945Q38960854-EBD92153-0A62-4D3C-B835-B174766AD810Q38984981-ECA3307E-3DB1-454B-A47F-FEF9A8C99F51Q39046213-260EDAAB-C8F0-4C54-B001-EA449EE9A79BQ39263983-F0A02C34-BBCD-4A6D-8216-BC42F2C8E600Q40039520-24EE0D06-7D02-47DA-85E8-B00B75DC3296Q40061894-FC6F48E6-D1C9-420E-962E-D2FC652DD82AQ40067748-C5F62135-3C00-4A8E-AD82-AB2F438872C0Q52855510-9AB20600-935F-4C1A-A6B8-F32A5158ABEBQ58711606-5DB87C77-A490-4586-8E42-D0034FF06803
P2860
PML risk stratification using anti-JCV antibody index and L-selectin.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
PML risk stratification using anti-JCV antibody index and L-selectin.
@en
PML risk stratification using anti-JCV antibody index and L-selectin.
@nl
type
label
PML risk stratification using anti-JCV antibody index and L-selectin.
@en
PML risk stratification using anti-JCV antibody index and L-selectin.
@nl
prefLabel
PML risk stratification using anti-JCV antibody index and L-selectin.
@en
PML risk stratification using anti-JCV antibody index and L-selectin.
@nl
P2093
P2860
P50
P356
P1476
PML risk stratification using anti-JCV antibody index and L-selectin
@en
P2093
Anita Posevitz-Fejfár
Annett Jacobi
Björn Tackenberg
Béatrice Pignolet
David Brassat
Ester Cantó
Felix Luessi
Ingrid Meinl
Johanna Breuer
Manuel Comabella
P2860
P304
P356
10.1177/1352458515607651
P50
P577
2015-10-02T00:00:00Z